| 1. |
|
|
| 2. |
- Getahun, H, et al.
(author)
-
Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries
- 2015
-
In: The European respiratory journal. - : European Respiratory Society (ERS). - 1399-3003 .- 0903-1936. ; 46:6, s. 1563-1576
-
Journal article (peer-reviewed)abstract
- Latent tuberculosis infection (LTBI) is characterised by the presence of immune responses to previously acquired Mycobacterium tuberculosis infection without clinical evidence of active tuberculosis (TB). Here we report evidence-based guidelines from the World Health Organization for a public health approach to the management of LTBI in high risk individuals in countries with high or middle upper income and TB incidence of <100 per 100 000 per year. The guidelines strongly recommend systematic testing and treatment of LTBI in people living with HIV, adult and child contacts of pulmonary TB cases, patients initiating anti-tumour necrosis factor treatment, patients receiving dialysis, patients preparing for organ or haematological transplantation, and patients with silicosis. In prisoners, healthcare workers, immigrants from high TB burden countries, homeless persons and illicit drug users, systematic testing and treatment of LTBI is conditionally recommended, according to TB epidemiology and resource availability. Either commercial interferon-gamma release assays or Mantoux tuberculin skin testing could be used to test for LTBI. Chest radiography should be performed before LTBI treatment to rule out active TB disease. Recommended treatment regimens for LTBI include: 6 or 9 month isoniazid; 12 week rifapentine plus isoniazid; 3–4 month isoniazid plus rifampicin; or 3–4 month rifampicin alone.
|
|
| 3. |
- Mikityuk, K., et al.
(author)
-
Horizon-2020 ESFR-SMART project on Sodium Fast Reactor Safety: status after 18 months
- 2019
-
Conference paper (other academic/artistic)abstract
- To improve the public acceptance of the future nuclear power in Europe we have to demonstrate that the new reactors have significantly higher safety level compared to traditional reactors. The ESFR-SMART project (European Sodium Fast Reactor Safety Measures Assessment and Research Tools) aims at enhancing further the safety of Generation-IV SFRs and in particular of the commercial-size European Sodium Fast Reactor (ESFR) in accordance with the European Sustainable Nuclear Industrial Initiative (ESNII) roadmap and in close cooperation with the Advanced Sodium Technological Reactor for Industrial Demonstration (ASTRID) program. The project aims at 5 specific objectives: 1. Produce new experimental data in order to support calibration and validation of the computational tools for each defence-in-depth level. 2. Test and qualify new instrumentations in order to support their utilization in the reactor protection system. 3. Perform further calibration and validation of the computational tools for each defence-in-depth level in order to support safety assessments of Generation-IV SFRs, using the data produced in the project as well as selected legacy data. 4. Select, implement and assess new safety measures for the commercial-size ESFR, using the GIF methodologies, the FP7 CP-ESFR project legacy, the calibrated and validated codes and being in accordance with the update of the European and international safety frameworks taking into account the Fukushima accident. 5. Strengthen and link together new networks, in particular, the network of the European sodium facilities and the network of the European students working on the SFR technology. By addressing the industry, policy makers and general public, the project is expected to make a meaningful impact on economics, environment, EU policy and society. Selected results and milestones achieved during the first eighteen months of the project will be briefly presented, including − proposal of new safety measures for ESFR; − evaluation of ESFR core performance; − benchmarking of codes; − experimental programs; and − education and training.
|
|
| 4. |
- Gaudino, Mario, et al.
(author)
-
Coronary artery bypass grafting versus medical therapy in patients with stable coronary artery disease: An individual patient data pooled meta-analysis of randomized trials.
- 2024
-
In: The Journal of thoracic and cardiovascular surgery. - : Elsevier BV. - 1097-685X .- 0022-5223. ; 167:3
-
Journal article (peer-reviewed)abstract
- It is unclear whether coronary artery bypass grafting (CABG) improves survival compared with medical therapy (MT) in patients with stable coronary artery disease (CAD). The aim of this analysis was to perform an individual-patient data-pooled meta-analysis of contemporary randomized controlled trials that compared CABG and MT in patients with stable CAD.A systematic search was performed in January 2021 to identify randomized controlled trials enrolling adult patients with stable CAD, randomized to CABG or MT. Only trials using at least aspirin, beta-blockers, and statins in the MT arm were included. Individual patient data were obtained from all eligible studies and pooled. The primary outcome was all-cause mortality.Four trials involving 2523 patients (1261 CABG; 1262MT) were included with a median follow-up of 5.6 (4.0-9.2) years. CABG was associated with increased risk of all-cause mortality within 30days (hazard ratio [HR], 4.81; 95% confidence interval [CI], 1.95-11.83) but subsequent reduction in the long-term risk of death (HR, 0.79; 95% CI, 0.69-0.89). As such, the cumulative 10-year mortality rate was lower in patients treated with CABG compared with MT (45.1% vs 51.7%, respectively; odds ratio, 0.70; 95% CI, 0.58-0.85). Age and race were significant treatment effect modifier (interaction P=.003 for both).In patients with stable CAD, initial allocation to CABG was associated with greater periprocedural risk of death but improved long-term survival compared with MT. The survival advantage for CABG became significant after the fourth postoperative year and was particularly pronounced in younger and non-White patients.
|
|
| 5. |
- Kuijper, J. C., et al.
(author)
-
PU and MA management in thermal htgrs - impact at fuel, reactor and fuel cycle levels
- 2009
-
In: 2008 Proceedings of the 4th International Topical Meeting on High Temperature Reactor Technology, HTR 2008. - 9780791848548 ; , s. 73-81
-
Conference paper (peer-reviewed)abstract
- The PUMA project, a Specific Targeted Research Project (STREP) of the European Union EURATOM 6th Framework Program, is mainly aimed at providing additional key elements for the utilisation and transmutation of plutonium and minor actinides (neptunium and americium) in contemporary and future (high temperature) gas-cooled reactor design, which are promising tools for improving the sustainability of the nuclear fuel cycle. PUMA would also contribute to the reduction of Pu and MA stockpiles and to the development of safe and sustainable reactors for C02-free energy generation. The project runs from September 1, 2006 until August 31, 2009. PUMA also contributes to technological goals of the Generation IV International Forum. It contributes to developing and maintaining the competence in reactor technology in the EU and addresses European stakeholders on key issues for the future of nuclear energy in the EU. An overview is presented of the status of the project at mid-term.
|
|
| 6. |
|
|
| 7. |
- Atun, Rifat, et al.
(author)
-
Sustainable care for children with cancer : a Lancet Oncology Commission
- 2020
-
In: The Lancet Oncology. - 1470-2045. ; 21:4, s. 185-224
-
Research review (peer-reviewed)abstract
- We estimate that there will be 13·7 million new cases of childhood cancer globally between 2020 and 2050. At current levels of health system performance (including access and referral), 6·1 million (44·9%) of these children will be undiagnosed. Between 2020 and 2050, 11·1 million children will die from cancer if no additional investments are made to improve access to health-care services or childhood cancer treatment. Of this total, 9·3 million children (84·1%) will be in low-income and lower-middle-income countries. This burden could be vastly reduced with new funding to scale up cost-effective interventions. Simultaneous comprehensive scale-up of interventions could avert 6·2 million deaths in children with cancer in this period, more than half (56·1%) of the total number of deaths otherwise projected. Taking excess mortality risk into consideration, this reduction in the number of deaths is projected to produce a gain of 318 million life-years. In addition, the global lifetime productivity gains of US$2580 billion in 2020–50 would be four times greater than the cumulative treatment costs of $594 billion, producing a net benefit of $1986 billion on the global investment: a net return of $3 for every $1 invested. In sum, the burden of childhood cancer, which has been grossly underestimated in the past, can be effectively diminished to realise massive health and economic benefits and to avert millions of needless deaths.
|
|
| 8. |
- Briz, V, et al.
(author)
-
The non-coding RNA BC1 regulates experience-dependent structural plasticity and learning
- 2017
-
In: Nature communications. - : Springer Science and Business Media LLC. - 2041-1723. ; 8:1, s. 293-
-
Journal article (peer-reviewed)abstract
- The brain cytoplasmic (BC1) RNA is a non-coding RNA (ncRNA) involved in neuronal translational control. Absence of BC1 is associated with altered glutamatergic transmission and maladaptive behavior. Here, we show that pyramidal neurons in the barrel cortex of BC1 knock out (KO) mice display larger excitatory postsynaptic currents and increased spontaneous activity in vivo. Furthermore, BC1 KO mice have enlarged spine heads and postsynaptic densities and increased synaptic levels of glutamate receptors and PSD-95. Of note, BC1 KO mice show aberrant structural plasticity in response to whisker deprivation, impaired texture novel object recognition and altered social behavior. Thus, our study highlights a role for BC1 RNA in experience-dependent plasticity and learning in the mammalian adult neocortex, and provides insight into the function of brain ncRNAs regulating synaptic transmission, plasticity and behavior, with potential relevance in the context of intellectual disabilities and psychiatric disorders.
|
|
| 9. |
|
|
| 10. |
- Girardi, P., et al.
(author)
-
Anti-Toxin Responses to Natural Enterotoxigenic Escherichia coli (ETEC) Infection in Adults and Children in Bangladesh
- 2023
-
In: Microorganisms. - 2076-2607. ; 11:10
-
Journal article (peer-reviewed)abstract
- A sero-epidemiology study was conducted in Dhaka, Bangladesh between January 2020 and February 2021 to assess the immune responses to ETEC infection in adults and children. (1) Background: Enterotoxigenic Escherichia coli infection is a main cause of diarrheal disease in endemic countries. The characterization of the immune responses evoked by natural infection can guide vaccine development efforts. (2) Methods: A total of 617 adult and 480 pediatric diarrheal patients were screened, and 43 adults and 46 children (below 5 years of age) with an acute ETEC infection completed the study. The plasma samples were analyzed for antibody responses against the ETEC toxins. (3) Results: Heat-stable toxin (ST)-positive ETEC is the main cause of ETEC infection in adults, unlike in children in an endemic setting. We detected very low levels of anti-ST antibodies, and no ST-neutralizing activity. However, infection with ETEC strains expressing the heat-labile toxin (LT) induced systemic antibody responses in less than 25% of subjects. The antibody levels against LTA and LTB, as well as cholera toxin (CT), correlated well. The anti-LT antibodies were shown to have LT- and CT- neutralizing activity. The antibody reactivity against linear LT epitopes did not correlate with toxin-neutralizing activity. (4) Conclusions: Unlike LT, ST is a poor antigen and even adults have low anti-ST antibody levels that do not allow for the detection of toxin-neutralizing activity.
|
|
